SPRO · Spero Therapeutics, Inc.
$1.21
+0.05 (+4.31%)
Market Cap
$67.17M
Shares
57.90M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Esther Rajavelu | CEO | $2,061,496 |
| Satyavrat Shukla | CEO | $2,025,178 |
| Tim Keutzer | COO | $1,440,820 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Satyavrat Shukla | CEO | $1,953,237 |
| Tim Keutzer | COO | $1,033,450 |
| Esther Rajavelu | CEO | $856,479 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Ankit Mahadevia | CEO | $2,385,905 |
| Satyavrat Shukla | CEO | $2,024,648 |
| Tamara Joseph | Chief Legal Officer | $1,455,126 |
| Timothy Keutzer | COO | $1,438,569 |
| Tim Keutzer | COO | $1,438,569 |
| Esther Rajavelu | CEO | $458,054 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ankit Mahadevia | CEO | $4,239,705 |
| Satyavrat Shukla | CEO | $1,673,070 |
| Tamara Joseph | Chief Legal Officer | $1,625,358 |
| Timothy Keutzer | COO | $1,585,037 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ankit Mahadevia | CEO | $4,875,045 |
| Satyavrat Shukla | CEO | $2,228,271 |
| Cristina Larkin | COO | $1,903,930 |
| Tamara Joseph | Chief Legal Officer | $980,075 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Ankit Mahadevia | CEO | $2,120,788 |
| David Melnick | Chief Medical Officer | $999,913 |
| Christina Larkin | COO | $991,962 |
| Cristina Larkin | COO | $991,962 |
| Satyavrat Shukla | CFO | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Ankit Mahadevia | CEO | $1,789,374 |
| Christina Larkin | COO | $947,983 |
| David Melnick | Chief Medical Officer | $939,789 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| David Melnick | Chief Medical Officer | $1,634,361 |
| Ankit Mahadevia | CEO | $721,324 |
| Christina Larkin | COO | $533,799 |